The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review

Objective Over the last few decades clinicians have become aware that cognitive impairment might be a major cause of disability, loss employment and poor quality life in patients suffering from multiple sclerosis [MS]. The impact disease modifying therapies [DMTs] on cognition is still matter debate. Theoretically, DMTs could exert substantial beneficial effect by means reducing neuroinflammation brain atrophy, which are established correlates dysfunction. aim study was to review evidence concerning functions. Methods PubMed, Scopus, European Committee for Treatment Research Multiple Sclerosis [ECTRIMS] Library were searched articles pediatric adult populations with sclerosis, including clinical trials RWD, where psychometric results analyzed as secondary or exploratory endpoints. Results We reviewed total 44 studies found our search strategy, psychological tests applied, length follow-up, possible limitations. pointed out difficulties associated assessing DMTs’ effects functions, pitfalls tools used evaluating MS patients. Conclusion There need highlight this aspect therapies, collect adequate data make informed therapeutic decisions, improve understanding MS-related dysfunction provide new targets.